FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to nitrogen oxide-releasing compounds, applied for retardation of development or complete reversion of muscular dystrophy, such as Duchenne dystrophy or Becker dystrophy.
EFFECT: obtaining compounds for retardation of development or complete reversion of muscular dystrophies.
4 cl, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF NITROOXYDERIVATIVE DRUG FOR TREATING MUSCULAR DYSTROPHY | 2007 |
|
RU2429828C2 |
| NITROOXYDERIVATIVES OF FLUVASTATIN, PRAVASTATIN, CERIVASTATIN, ATOVASTATIN AND ROSUVASTATIN AS CHOLESTEROL-REDUCING AGENTS WITH IMPROVED ANTI-INFLAMMATORY, ANTITHROMBOTIC, ANTI-THROMBOCYTIC ACTIVITY | 2004 |
|
RU2362770C2 |
| PRODRUGS OF MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | 2014 |
|
RU2659220C2 |
| NITROOXYDERIVATIVE STEROIDS | 2006 |
|
RU2415864C2 |
| NITROESTERS OF CORTICOID COMPOUNDS | 1997 |
|
RU2186781C2 |
| PHOSPHODIESTERASE TYPE 5 INHIBITOR RELEASING NITROGEN OXIDE | 2019 |
|
RU2785776C2 |
| TRIAZOLES FOR REGULATION OF INTRACELLULAR CALCIUM HOMEOSTASIS | 2017 |
|
RU2753509C2 |
| STEROIDS THAT RELEASE NITROGEN OXIDE | 2008 |
|
RU2442790C2 |
| NITROOXY-DERIVATIVES OF LOSARTAN, VALSARTAN, CANDESARTAN, TELMISARTAN EPROSARTAN AND OLMESARTAN AS BLOCKERS OF ANGIOTENSIN II RECEPTORS FOR TREATING CARDIOVASCULAR DISEASES | 2004 |
|
RU2374240C2 |
| ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS SHOWING IMPROVED BIOAVAILABILITY | 2003 |
|
RU2323003C2 |
